The new paradigm of hepatitis C therapy: Integration of oral therapies into best practices

Journal of Viral Hepatitis

Volumn 20, Issue 11, 2013, Pages 745-760

  Afdhal, N H ^a   Zeuzem, S ^b   Schooley, R T ^c   Thomas, D L ^d   Ward, J W ^e   Litwin, A H ^f   Razavi, H ^g   Castera, L ^h   Poynard, T ⁱ   Muir, A ^j   Mehta, S H ^k   Dee, L ^l   Graham, C ^m   Church, D R ⁿ   Talal, A H ^o   Sulkowski, M S ^d   Jacobson, I M ^p  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g Center for Disease Analysis   (United States)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^k JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^l Fair Pricing Coalition and AIDS Action Baltimore   (United States)

^m BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁿ MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^o UNIVERSITY AT BUFFALO   (United States)

^p WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

diagnosis; directly acting antiviral agents; health services; hepatitis C; pharmacoeconomics

Indexed keywords

ABT 267; ABT 333; ABT 450; ASUNAPREVIR; BMS 791325; BOCEPREVIR; DACLATASVIR; DANOPREVIR; DELEOBUVIR; FALDAPREVIR; LEDIPASVIR; MERICITABINE; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DISEASE CONTROL; DRUG ADMINISTRATION ROUTE; HEPATITIS C; HUMAN; MEDICAL SPECIALIST; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING TEST; UNITED STATES;

DIAGNOSIS; DIRECTLY ACTING ANTIVIRAL AGENTS; HEALTH SERVICES; HEPATITIS C; PHARMACOECONOMICS;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); HEPATITIS C, CHRONIC; HUMANS; LIVER; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84885444012     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12173     Document Type: Review

References (113)

1. Kwo PY, Lawitz EJ, McCone J, et al,. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
2. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
4. McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
5. Fontaine H, Pol S,. Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients. Clin Res Hepatol Gastroenterol 2011; 35 (Suppl. 2): S59-S63.
6. Gane EJ, Stedman CA, Hyland RH, et al,. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
7. Poordad F, Lawitz E, Kowdley KV, et al,. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53.
8. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877.
9. Centers for Disease Control Prevention (CDC). Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011; 60: 537-541.
10. Ngo-Metzger Q, Ward JW, Valdiserri RO,. Expanded hepatitis C virus screening recommendations promote opportunities for care and cure. Ann Intern Med 2013; 159: 364-365.
11. Kowdley KV, Lawitz E, Poordad F, et al,. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/- ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR Study. J Hepatol 2013; 58 (Suppl. S1): S2.
12. Lawitz E, Ghalib R, Rodriguez-Torres M, et al,. Suppression of viral load through 4 weeks post-treatment results of a once-daily regimen of simeprevir + sofosbuvir with or without ribavirin in hepatitis C virus GT 1 null responders. Program and Abstracts of the 20th Conference on Retroviruses and Opportunistic Infections 2013; Abstract 155LB.
13. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al,. Sustained virologic response with daclatasvir plus sofosbuvir +/- ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). J Hepatol 2013; 58 (Suppl. 1): S570.
14. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al,. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. Hepatology 2012; 56 (Suppl. S1): Abstract LB-2.
15. Zeuzem S, Soriano V, Asselah T, et al,. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-639.
16. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD,. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278.
17. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714. (Pubitemid 46780630)
18. Smith BD, Patel N, Beckett GA, Jewett A, Ward JW,. Hepatitis C virus antibody prevalence, correlates and predictors among persons born from 1945 through 1965, United States, 1999-2008. Hepatology 2011; 54 (Suppl. S1): Abstract 241.
19. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47 (RR-19): 1-39.
20. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
21. Dienstag JL, McHutchison JG,. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225-230. (Pubitemid 43049855)
22. Roblin DW, Smith BD, Weinbaum CM, Sabin ME,. HCV screening practices and prevalence in an MCO, 2000-2007. Am J Manag Care 2011; 17: 548-555.
23. Southern WN, Drainoni M-L, Smith BD, et al,. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat 2011; 18: 474-481.
24. Volk ML, Tocco R, Saini S, Lok ASF,. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50: 1750-1755.
25. Smith BD, Morgan RL, Beckett GA, et al,. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32.
26. Rein DB, Smith BD, Wittenborn JS, et al,. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 263-270.
27. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y,. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329-337.
28. Van der Meer AJ, Veldt BJ, Feld JJ, et al,. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.
29. Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in Adults: U.S. preventive services task force recommendation statement. Ann Intern Med 2013; 159: 349-357.
30. Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE,. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis 2013; 56: 1382-1393.
31. McEwan P, Ward T, Yuan Y, Kim R, L'italien G,. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 2013; 58: 54-64.
32. Litwin AH, Smith BD, Drainoni M-L, et al,. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis 2012; 44: 497-503.
33. Centers for Disease Control Prevention (CDC). Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013; 62: 362-365.
34. Smith BD, Teshale E, Jewett A, et al,. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin Infect Dis 2011; 53: 780-786.
35. Jewett A, Smith BD, Garfein RS, Cuevas-Mota J, Teshale EH, Weinbaum CM,. Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. J Clin Virol 2012; 54: 213-217.
36. Baranova A, Lal P, Birerdinc A, Younossi ZM,. Non-Invasive markers for hepatic fibrosis. BMC Gastroenterol 2011; 11: 91.
37. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
38. Chou R, Wasson N,. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158: 807-820.
39. Lin Z-H, Xin Y-N, Dong Q-J, et al,. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-736.
40. Castéra L, Foucher J, Bernard P-H, et al,. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-835.
41. Friedrich-Rust M, Ong M-F, Martens S, et al,. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974.
42. Degos F, Perez P, Roche B, et al,. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53: 1013-1021.
43. Klibansky DA, Mehta SH, Curry M, Nasser I, Challies T, Afdhal NH,. Transient elastography for predicting clinical outcomes in patients with chronic liver disease. J Viral Hepat 2012; 19: e184-e193.
44. Vergniol J, Foucher J, Terrebonne E, et al,. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-1979.
45. Castéra L, Vergniol J, Foucher J, et al,. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350. (Pubitemid 40439195)
46. Poynard T, Ingiliz P, Elkrief L, et al,. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS ONE 2008; 3: e3857.
47. Bonder A, Afdhal NH,. Biopsy no more; changing the screening and diagnostic algorithm for hepatitis C. Clin Gastroenterol Hepatol 2013; 11: 309-310.
48. Holmberg SD, Spradling PR, Moorman AC, Denniston MM,. Hepatitis C in the United States. N Engl J Med 2013; 368: 1859-1861.
49. Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS,. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr 2004; 37: 1367-1375. (Pubitemid 39435051)
50. Ong JP, Collantes R, Pitts A, Martin L, Sheridan M, Younossi ZM,. High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol 2005; 39: 826-830. (Pubitemid 41361902)
51. Schaefer M, Capuron L, Friebe A, et al,. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012; 57: 1379-1390.
52. Miller L, Fluker S-A, Osborn M, Liu X, Strawder A,. Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic. J Natl Med Assoc 2012; 104: 244-250.
53. Morrill JA, Shrestha M, Grant RW,. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20: 754-758. (Pubitemid 41141009)
54. Mehta SH, Genberg BL, Astemborski J, et al,. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-133.
55. Blasiole JA, Shinkunas L, Labrecque DR, Arnold RM, Zickmund SL,. Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol 2006; 12: 4665-4672. (Pubitemid 44269725)
56. Treloar C, Newland J, Rance J, Hopwood M,. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat 2010; 17: 839-844.
57. Khokhar OS, Lewis JH,. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci 2007; 52: 1168-1176. (Pubitemid 46626189)
58. Zickmund SL, Brown KE, Bielefeldt K,. A systematic review of provider knowledge of hepatitis C: is it enough for a complex disease? Dig Dis Sci 2007; 52: 2550-2556. (Pubitemid 47373918)
59. Shehab TM, Sonnad SS, Lok AS,. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat 2001; 8: 377-383. (Pubitemid 34205892)
60. Kanwal F, Hoang T, Spiegel BMR, et al,. Predictors of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors. Hepatology 2007; 46: 1741-1749.
61. Stoové MA, Gifford SM, Dore GJ,. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 2005; 77: 81-86. (Pubitemid 39656102)
62. Mitchell AE, Colvin HM, Palmer Beasley R,. Institute of medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51: 729-733.
63. Volk ML,. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother 2010; 65: 1327-1329.
64. Arora S, Thornton K, Murata G, et al,. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364: 2199-2207.
65. Razavi H, El Khoury A, Elbasha E, et al,. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57: 2164-2170.
66. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI,. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011; 17: 531-546.
67. Di Bisceglie AM, Lyra AC, Schwartz M, et al,. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003; 98: 2060-2063. (Pubitemid 37185806)
68. Davis GL, Albright JE, Cook SF, Rosenberg DM,. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338. (Pubitemid 36443043)
69. El Khoury AC, Klimack WK, Wallace C, Razavi H,. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat 2012; 19: 153-160.
70. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM,. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 2010; 8: 1017-1029.
71. Gellad ZF, Reed SD, Muir AJ,. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. Antivir Ther 2012; 17 (6 Pt B): 1189-1199.
72. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD,. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156: 279-290.
73. Bichoupan K, Martel-Laferriere V, Ng M, et al,. Real world costs of telaprevir-based triple therapy, including costs of managing adverse events, at the Mount Sinai Medical Center, NY: 147,000 per EOT. J Hepatol 2013; 58 (Suppl. 1): S324-S325.
74. Hallinan R, Byrne A, Agho K, Dore GJ,. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 2007; 88: 49-53. (Pubitemid 46400306)
75. Jowett SL, Agarwal K, Smith BC, et al,. Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001; 94: 153-158. (Pubitemid 32242003)
76. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH,. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013; 56: 806-816.
77. Harris KA Jr, Arnsten JH, Litwin AH,. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010; 4: 20-26.
78. Martinez AD, Dimova R, Marks KM, et al,. Integrated internist-addiction medicine-hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat 2012; 19: 47-54.
79. Sylvestre DL, Zweben JE,. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007; 18: 406-410. (Pubitemid 47381423)
80. Alavi M, Grebely J, Micallef M, et al,. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clin Infect Dis 2013; 57 (Suppl. 2): S62-S69.
81. Bruggman P, Litwin AH,. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis 2013; 57 (Suppl. 2): S56-S61.
82. Evon DM, Simpson K, Kixmiller S, et al,. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol 2011; 106: 1777-1786.
83. Moussalli J, Delaquaize H, Boubilley D, et al,. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract 2010; 2010: article ID 261472.
84. Robaeys G, Grebely J, Mauss S, et al,. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013; 57 (Suppl. 2): S129-S137.
85. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P,. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57 (Suppl. 2): S39-S45.
86. Hellard ME, Jenkinson R, Higgs P, et al,. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust 2012; 196: 638-641.
87. Fontaine H, Hezode C, Dorival C, et al,. SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 221 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC). J Hepatol 2013; 58 (Suppl. 1): S27.
88. Lawitz E, Wyles D, Davis M, et al,. Sofosbuvir + peginterferon + ribavirin for 12 weeks achieves 90% SVR12 in genotype 1, 4, 5, or 6 HCV infected patients: The Neutrino Study. J Hepatol 2013; 58 (Suppl. 1): S567.
89. Soriano V, Gane EJ, Angus PW, et al,. Efficacy and safety of the interferon (IFN)-free combination of BI 201335+ BI 207127+/- ribavirin (RBV) in treatment-naive patients with HCV genotype (GT) 1 infection and compensated liver cirrhosis: results from the SOUND-C2 study. Hepatology 2012; 56 (Suppl. S1): 234A.
90. Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK,. Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment Pharmacol Ther 2006; 24: 585-591. (Pubitemid 44127839)
91. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al,. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450. (Pubitemid 38988593)
92. Sulkowski MS, Sherman KE, Dieterich DT, et al,. Combination therapy with telaprevir for chronic hepatitis C Virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96.
93. Sulkowski M, Pol S, Mallolas J, et al,. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.
94. Dieterich D, Soriano V, Nelson M, et al,. STARTVerso 4: High rates of early virologic response in hepatitis C virus genotype 1/HIV co-infected patients treated with fladaprevir + pegylated interferon and ribavirin. Program and Abstracts of the 20th Conference on Retroviruses and Opportunistic Infections 2013 Mar 3; Abstract 40LB.
95. Dieterich D, Rockstroh JK, Orkin C, et al,. Simeprevir with pegylated interferon/ribavirin in patients co-infected with chronic hepatitis C virus and HIV-1:Week-24 interim analysis of the TMC435-C212 Study. Program and Abstracts of the 20th Conference on Retroviruses and Opportunistic Infections 2013 Mar 3; Abstract 154LB.
96. Limketkai BN, Mehta SH, Sutcliffe CG, et al,. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308: 370-378.
97. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
98. Everson GT, Sims KD, Rodriguez-Torres M, et al,. An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94% in treatment-naive patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection. Hepatology 2012; 56 (Suppl. S1): Abstract LB-3.
99. Gane EJ, Pockros P, Zeuzem S, et al,. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-naive HCV genotype 1-infected patients. J Hepatol 2012; 56 (Suppl. 2): S555-S5556.
100. Gane EJ, Stedman CA, Hyland RH, Ding X, Pang PS, Symonds WT,. ELECTRON: 100% SVR rates for once-daily sofosbuvir plus ledipasvir plus ribavirin given for 12 weeks in treatment-naive and previously treated patients with HCV genotype 1. Program and Abstracts of the 20th Conference on Retroviruses and Opportunistic Infections 2013 Mar 3; Abstract 41LB.
101. Gane E, Lawitz E, Rodriguez-Torres M, et al,. Phase 3 randomized controlled trial of all-oral treatment with sofosbuvir + ribavirin for 12 weeks compared to 24 weeks of PEG + ribavirin in treatment-naive GT2/3 HCV-infected patients. J Hepatol 2013; 58 (Suppl. 1): S3.
102. Lok AS, Gardiner DF, Lawitz E, et al,. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224.
103. Suzuki F, Ikeda K, Toyota J, et al,. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1B-infected null responders or ineligible/ intolerant to peginterferon/ribavirin. J Hepatol 2012; 56 (Suppl. 2): S7-S8.
104. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK,. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-659.
105. Adeyemi OM, Jensen D, Attar B, et al,. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDS 2004; 18: 239-245. (Pubitemid 38552655)
106. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ,. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288-292. (Pubitemid 34150758)
107. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D,. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36: 97-100. (Pubitemid 36099103)
108. Grebely J, Raffa JD, Lai C, et al,. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-358.
109. Groom H, Dieperink E, Nelson DB, et al,. Outcomes of a Hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol 2008; 42: 97-106.
110. Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR,. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med 2004; 19: 357-365.
111. Mehta SH, Lucas GM, Mirel LB, et al,. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20: 2361-2369. (Pubitemid 44789539)
112. Restrepo A, Johnson TC, Widjaja D, et al,. The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat 2005; 12: 86-90. (Pubitemid 40188779)
113. Rocca LG, Yawn BP, Wollan P, Kim WR,. (2004) Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med 2: 116-124. (Pubitemid 39329078)